Masimo Malaysia Unveils Its First Medical Device Production Facility in Johor

Masimo Malaysia Unveils Its First Medical Device Production Facility in Johor

Empowering Healthcare Innovation, Revolutionising Patient Care

Pasir Gudang, Johor, 5 March 2024 – Masimo Medical Technologies Malaysia Sdn. Bhd. (Masimo Malaysia), a mission-based medical device and technology company known for solving “unsolvable” problems in patient care, proudly announces the grand opening of its first facility in Pasir Gudang, Johor. This milestone event marks the culmination of months of meticulous planning, dedication, and collaboration, positioning Masimo as a leading player in advancing medical technology and patient care in Malaysia. In recognition of Malaysia’s essential role in fostering medical innovation and investment, the grand opening ceremony was attended by distinguished guests and dignitaries, including government officials from the Malaysian Investment Development Authority (MIDA).

Masimo Malaysia, stands as the sole manufacturer in the country, producing the “Pulse Oximetry Adhesive Sensor and Pulse Oximeter.” These testing tools used to measure the pulse rate and the level of oxygen (oxygen saturation) in the blood. The “Pulse Oximetry Adhesive Sensor” is a disposable, single-patient-use sensor designed for use with the Masimo system, particularly SET (Signal Extraction Technology – The technology that allows accurate monitoring of arterial oxygen saturation and pulse rate, even during motion). Meanwhile, the “Pulse Oximeter” is designed as a portable, handheld, and battery-powered continuous pulse oximeter monitoring device.

Strategically located near key seaports and international airports, the 133,000 square feet facility boasts cutting-edge production areas and warehouse spaces designed to facilitate the development and distribution of innovative medical solutions. With a total build-up area of 133,000 square feet, including a production area spanning 81,220 square feet and a warehouse area covering 46,631 square feet, the company is poised to enhance its manufacturing capabilities and meet the growing demand for high-quality medical devices.

Datuk Wira Arham Abdul Rahman, CEO of MIDA, expressed, “The opening of Masimo Medical Technologies Malaysia’s facility is a clear testament to the country’s growing influence in the global medical technology landscape. It is not only signifying a major leap for Masimo Malaysia but also strengthens the medical devices ecosystem in the Southern Region. It underscores the confidence in Malaysia’s business-friendly environment and the robustness of our medical device supply chain, affirming the country’s status as a preferred destination for high-value manufacturing and innovation-driven investments. This fully export-oriented project will be supported by Malaysian technical workforce with more than 27% of the total manpower ranging from managerial, technical, and supervisory category.”

“The initiative aligns with the New Industrial Master Plan 2030, aiming for a more integrated medical devices industry to enhance competitiveness through better resource use, cost savings, increased innovation, and advanced product development. MIDA is excited to support Masimo Malaysia’s growth, which complements our strategy to make Malaysia a leading hub for medical technology development and manufacturing.”, added Datuk Wira Arham.

“We are thrilled to celebrate the grand opening of Masimo Medical Technologies Malaysia Sdn. Bhd. and reaffirm our commitment to advancing medical technology and patient care in Malaysia,” said Mr. Jayakumar Krishnan, Plant Manager of Masimo Medical Technologies Malaysia Sdn. Bhd. “Our cutting-edge facility represents a significant investment in the future of healthcare, and we are excited to leverage Malaysia’s strategic location and robust infrastructure to drive innovation and growth in the region.”, he added.

Since its inception in September 2022, Masimo Medical Technologies Malaysia Sdn. Bhd. has made significant strides in establishing its presence in the region. From the commencement of the hiring process and site commissioning to the completion of production area renovations and commencement of direct labour hiring, the company has demonstrated unwavering commitment and determination in realising its vision of improving patient outcomes and reducing the cost of care.

As the company embarks on this new chapter of growth and expansion, it remains steadfast in its mission to improve patient outcomes and revolutionise the healthcare industry through innovation, collaboration, and excellence.

In 2023, the medical devices industry saw the approval of 26 projects, attracting investments totalling RM2.1 billion. Among these, nine new projects accounted for RM773.9 million (36.3%) of the investments, while the remaining 17 were expansion or diversification projects, contributing RM1.4 billion (63.7%).

– End –

About MIDA

MIDA is the government’s principal investment promotion and development agency under the Ministry of Investment, Trade and Industry (MITI) to oversee and drive investments into the manufacturing and services sectors in Malaysia. Headquartered in Kuala Lumpur Sentral, MIDA has 12 regional and 21 overseas offices. MIDA continues to be the strategic partner to businesses in seizing the opportunities arising from the technology revolution of this era. For more information, please visit www.mida.gov.my and follow us on X, Instagram, Facebook, LinkedIn, Tik Tok and YouTube.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns,3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97® and the Masimo W1® medical watch. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius T°® and Masimo W1 Sport.

Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at professional.masimo.com/evidence/featured-studies/feature/.

MIDA

Ms. Azlina Hamdan
Director, Life Sciences & Medical Technology Division
Tel: +603-2267 3791 Email:  [email protected]

Masimo

Ms. Daphne Tan
PR Director, XIN° Communications
Email: [email protected]